SML0613
罗非昔布
≥98% (HPLC)
别名:
4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
产品名称
罗非昔布, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(C)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3
InChI
1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
InChI key
RZJQGNCSTQAWON-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
相关类别
Biochem/physiol Actions
Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2.
Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.
Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.
Application
Rofecoxib has been used in high performance bioaffinity chromatography.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Gustavo C Machado et al.
Annals of the rheumatic diseases, 76(7), 1269-1278 (2017-02-06)
While it is now clear that paracetamol is ineffective for spinal pain, there is not consensus on the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) for this condition. We performed a systematic review with meta-analysis to determine the efficacy and safety
Robert E Marx
The International journal of oral & maxillofacial implants, 29(1), e37-e44 (2014-01-24)
The randomized prospective double-blinded clinical trial (RCT) is accepted as Level I evidence and is highly regarded. However, RCTs that gained FDA approval of drugs such as Vioxx, Fen-Phen, and oral and intravenous bisphosphonates have proven to generate misleading results
Kerstin Rabausch et al.
Circulation research, 96(1), e1-e6 (2004-12-14)
There is concern that cyclooxygenase (COX)-2 inhibitors may promote atherothrombosis by inhibiting vascular formation of prostacyclin (PGI2) and an increased thrombotic risk of COX-2 inhibitors has been reported. It is widely accepted that the prothrombotic effects of COX-2 inhibitors can
J Patrick O'Connor et al.
Acta orthopaedica, 80(5), 597-605 (2009-11-18)
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) activity, which is the rate-limiting enzyme in the synthesis of prostaglandins. Previous studies have indicated that NSAID therapy, and in particular NSAIDs that specifically target the inflammatory cyclooxygenase (COX-2), impair bone healing. We
Rosivaldo S Borges et al.
Molecules (Basel, Switzerland), 24(1) (2019-01-06)
A drug design for safer phenylbutazone was been explored by reactivity and docking studies involving single electron transfer mechanism, as well as toxicological predictions. Several approaches about its structural properties were performed through quantum chemistry calculations at the B3LYP level
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持